ThursdaySep 07, 2023 2:55 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its CFO Ryan Confer will be providing an overview of the company's pioneering gene therapies for cancer and diabetes at the upcoming H.C. Wainwright 25th Annual Global Investment Conference. Confer’s presentation is scheduled to begin at 3:00 p.m. ET on Wednesday, Sep. 13, 2023. Interested parties should visit https://ibn.fm/vvilS to register and access the presentation. A recording will be available for replay on Genprex’s website for a period of time. In addition, as detailed in the announcement, Confer…

Continue Reading

ThursdaySep 07, 2023 12:22 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be participating at the American Heart Association Scientific Sessions. The company announced that an abstract outlining long-term survival data from its ELPIS 1 trial of Lomecel-B(TM) for patients with HLHS has been accepted for presentation as a poster at upcoming Scientific Sessions. The sessions are slated to be held Nov. 11–13, 2023, in Philadelphia. The poster is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The…

Continue Reading

ThursdaySep 07, 2023 11:52 am

BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquires High Times Intellectual Property, Featured in Financial News Media Article

Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand in the cannabis industry. In addition to the Hightimes.com domain, the transaction also includes the trademarks for the Cannabis Cup and 420.com brands and their respective domain names. In exchange, High Times will receive a 19.9% stake in Lucy's outstanding stock as well as performance-based payments. “Lucy expects this acquisition to drive high margin revenue quickly and sustainably across the cannabis sector around the world. This is a great opportunity to grow the market presence of the nearly 50-year-old High…

Continue Reading

WednesdaySep 06, 2023 12:45 pm

BioMedNewsBreaks – HippoFi Inc. (ORHB) Collaborates to Bring ‘Innovative Technology to the Forefront of Spinal Treatments’

HippoFi (OTC: ORHB), a leading health care technology company and authority in spinal biologics, has announced a partnership with global medical technology leader Zimmer Biomet, aiming to redefine the spinal biologics landscape. According to the announcement, the collaboration will harness the combined expertise of both companies to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi’s subsidiary, PUR Biologics. Recognized as a leader in musculoskeletal innovations since 2013, PUR Biologics champions the advancement of regenerative medicine solutions. “Our collaboration with Zimmer Biomet is a significant stride in our journey to elevate the standards of…

Continue Reading

WednesdaySep 06, 2023 11:14 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.

BiondVax (NASDAQ: BVXV), a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by Israeli authorities on Aug. 31, is the company’s latest step to better reflect its fresh start and new direction. “We are incredibly optimistic about Scinai’s growth potential and ability…

Continue Reading

TuesdaySep 05, 2023 12:10 pm

BioMedNewsBreaks – Jaguar Health Inc. (NASDAQ: JAGX) Announces Investor Engagement Campaign with B2i Digital

Jaguar Health (NASDAQ: JAGX) was recently featured in a B2i release spotlighting the company’s focus on developing first-in-class, plant-based treatments for gastrointestinal (“GI”) disease. The release noted that JAGX and its family company Napo Pharmaceuticals are specifically looking at treating overactive bowel, which causes debilitating symptoms such as chronic debilitating diarrhea, GI urgency and GI incontinence in both humans and animals. The new initiative with B2i is part of a strategic campaign designed to increase investor engagement and interest.  “The most critical near-term catalysts are the expected availability in late Oct. 2023 of top-line results of Napo’s phase 3 clinical trial…

Continue Reading

TuesdaySep 05, 2023 12:00 pm

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

Longeveron (NASDAQ: LGVN, LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty, today announced that its management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference. The event is slated to take place in New York City from Sept. 11-13, 2023. Longeveron’s CEO Wa’el Hashad will give a pre-recorded presentation highlighting the company’s cellular therapy programs, which will be available on-demand by clicking here for the duration of the conference. The company’s CFO Lisa Locklear will also attend the…

Continue Reading

TuesdaySep 05, 2023 11:47 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS Pharmaceuticals CEO Climaco is scheduled to present during the two-day conference; his live webcast presentation is scheduled for Wednesday, Sept. 13, at 10:30 a.m. ET. In addition to the presentation, key CNPS officials will be available to participate in in-person and virtual one-on-one meetings with…

Continue Reading

WednesdayAug 30, 2023 11:08 am

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released a statement congratulating GEDiCube on its joint effort to accelerate early diagnosis of cancer in clinical trials. GEDiCube is partnering with NVIDIA Inception on clinical trials focused on advancing a unique platform for early cancer detection. The platform combines techniques for boosting the body’s natural tumor-fighting mechanisms with artificial intelligence and machine learning technology. “This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage,” said GEDiCube…

Continue Reading

WednesdayAug 30, 2023 10:16 am

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Participation at Upcoming National Investment Banking Association Conference

Longeveron (NASDAQ: LGVN; LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and aging-related frailty, will be presenting at the 149th annual Conference of the National Investment Banking Association. The annual conference is slated for Sept. 6–7, 2023, in Fort Lauderdale, Florida. According to the announcement, Longeveron CEO Wa’el Hashad will be providing an overview of the company, along with its cellular therapy programs. The company noted that its executive management team will also be at the presentation to discuss clinical trial progress and investment…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000